Formula Grant 2101TXSCID

This Project Grant award of $200,016, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports the research and development of a non-viral CRISPR/Cas9 genome editing therapy for Artemis-deficient severe combined immunodeficiency (ART-SCID). The primary awardee, The Regents of the University of California, San Francisco (UCSF), will develop expertise in non-viral genome editing of human...

This Cooperative Agreement award, with a total funding amount of $1,072,951, was granted by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The purpose of the award is to conduct a randomized clinical trial evaluating the efficacy and safety of low-dose versus moderate-dose busulfan conditioning regimens for hematopoietic cell transplantation in infants with severe combined immunodeficiency (SCID) due...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $438,682 to The Johns Hopkins University to conduct a multi-center observational study on silent cerebral infarction (SCI) in patients with immune thrombotic thrombocytopenic purpura (iTTP). The study aims to elucidate the natural history of SCI, establish the incidence and risk factors for new SCI and stroke during iTTP remission, and...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $563,588 to Weill Medical College of Cornell University to study the effects of immunosuppression on SARS-CoV-2 persistence, virus genetic diversity, and clinical outcomes of COVID-19. The research aims to determine the immune defects linked to prolonged SARS-CoV-2 replication in immunocompromised hosts, and...

This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $385,575.00 to the University of California, San Diego (UCSD) to investigate the underlying mechanisms of immune dysregulation and impaired wound healing in inherited STAT4-mediated autoinflammatory disease. The research aims to determine how gain-of-function mutations in the STAT4 gene lead to persistent...

This $1,120,805 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders federal grant program (CFDA 93.853), will support research to investigate how prior SARS-CoV-2 infection may increase the risk of vascular contributions to cognitive impairment and dementia (VCID). The research aims to: Determine how prior SARS-CoV-2 infection influences blood-brain barrier...

This Project Grant award from the National Center for Advancing Translational Sciences (NCATS), under CFDA Program 93.350, aims to evaluate the therapeutic potential of gene replacement for SCYL1 deficiency syndrome. The $158,500 award to Trustees of Indiana University, doing business as Indiana University Indianapolis, will support the engineering of two mouse models to enable inducible restoration of SCYL1 gene expression. This research represents a critical step towards developing a potential...

This Project Grant award of $811,009 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to develop a new technology called the Shear-Force Avidity-based Cell Selector (SACS) to assess functional immunity to influenza infection. The primary objectives are to: 1) enhance and optimize a microfluidic device to capture and separate B cells based on their B cell receptor (BCR) binding avidity to influenza...

This Project Grant award of $304,629 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports the preclinical development of LCTG-001, a human secretory IgA replacement therapy for patients with common variable immune deficiency (CVID). The goal is to deliver high molecular weight, human, polyclonal secretory antibodies directly to mucosal compartments to normalize nasal concentrations of secretory...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,815,882 five-year Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to The Regents of the University of California, San Francisco to expand and transform the Primary Immune Deficiency Treatment Consortium (PIDTC) into an open resource to study therapeutic outcomes and improve health outcomes for patients with inborn errors of immunity. The PIDTC will consolidate tools and infrastructure to...